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Case Report

A RARE CASE OF RAPIDLY ENLARGING
MYELOLIPOMA IN SICKLE CELL DISEASE
Paran Davari, BS1; Cortney Youens Lee, MD2; James Te-An Lee, MD3

ABSTRACT
Objective: Adrenal myelolipoma (AM) is a benign
tumor composed of mature fat cells and hemopoietic
elements. Most AMs are incidental findings on imaging
and clinically asymptomatic. The purpose of this case
report is to describe a rare case of AM and explore its clinical manifestations, imaging features, and treatment.
Methods: In this study, we report a case of a rapidly
growing right AM in a patient with uncontrolled hemoglobin sickle cell disease. A 38-year-old male presented to our
institution’s endocrine surgery clinic for evaluation of an
enlarging right adrenal mass. This mass was incidentally
found during an abdominal ultrasound performed for transaminitis and thrombocytopenia. Patient was asymptomatic
without any abdominal discomfort, back pain, nausea,
or vomiting.
Results: Patient was lost to follow up until 2018.
Follow-up computed tomography scan in 2018 showed the
right adrenal mass measuring 12.3 cm in greatest dimension with significant macroscopic fat. Given the imaging
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features, AM was the presumed diagnosis. However, with
a medical history of uncontrolled sickle cell disease, extramedullary hematopoiesis and rapidly growing liposarcoma
could not be ruled out. Surgical excision was performed
due to size and significant tumor growth. Diagnosis was
confirmed with histopathology and revealed myelolipoma.
Conclusion: Image characteristics can be helpful in
diagnosis of AM; however, the appearance of this lesion
on computed tomography can be similar to other adrenal
gland pathologies such as liposarcoma and mass-forming
extramedullary hematopoiesis. Percutaneous needle biopsy
may be indicated if the diagnosis remains unclear. (AACE
Clinical Case Rep. 2020;6:e54-e58)
Abbreviations:
AM = adrenal myelolipoma; CT = computed tomography; EMH = extramedullary hematopoiesis; SCD =
sickle cell disease
INTRODUCTION
With frequent use of imaging modalities, adrenal
masses are routinely discovered after cross-sectional
imaging. The differential diagnoses of adrenal incidentalomas include myelolipoma, pheochromocytoma,
congenital adrenal hyperplasia, adenoma, and carcinoma.
Biochemical testing and follow-up imaging are commonly
used to differentiate between these adrenal masses. Adrenal
myelolipoma (AM) is the only adrenal tumor with pathognomonic imaging features and can be diagnosed radiographically. These benign adrenal carcinomas are managed
conservatively and surgery is reserved for rapidly growing or symptomatic tumors (1). Here, we report a case of
a giant fat-containing right adrenal mass in a patient with
uncontrolled sickle cell disease (SCD).
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CASE REPORT
A 38-year-old man with a past medical history of type
2 diabetes mellitus and hemoglobin SCD presented for
initial evaluation to the endocrine surgery clinic in 2014.
He was referred for evaluation of an incidentally discovered right adrenal mass while undergoing an abdominal
ultrasound performed for transaminitis and thrombocytopenia (Fig. 1). The patient was asymptomatic without any
abdominal pain, weight gain, or symptoms attributable
to mass effect. His only complaint was fatigue which he
ascribed to his SCD. At this time, a biochemical profile
including plasma metanephrines and low-dose dexamethasone suppression test were normal. Given the significant
growth in size of the mass during the follow-up period, the
patient was scheduled for surgery but was lost to follow up.
He presented again to our clinic in 2018 to reestablish care
and discuss surgery.
Review of prior imaging studies performed for different clinical indications showed the right adrenal mass
measuring only 1 cm in 2001 and 4.4 cm in 2011 with
rapid growth on follow-up imaging studies (Fig. 2). An

Fig. 1. Sagittal ultrasound image of the right suprarenal region demonstrates a diffusely echogenic right adrenal mass.

A

abdominal magnetic resonance image without contrast (to
assess renal insufficiency) in 2014 showed an 8.4-cm right
adrenal mass demonstrating intermediate heterogenous
T2 signal most suggestive of soft-tissue signal intensity.
In-phase and opposed-phase T1 images and fat-suppressed
sequences confirmed both microscopic and macroscopic
fat, respectively (Fig. 3). In 2015, computed tomography
(CT) scans without contrast showed progressive enlargement to 9.6 cm and 10.1 cm with gross macroscopic fat.
Splenic and osseous changes consistent with known SCD
were also seen.
A follow-up CT scan in 2018 showed the right adrenal mass now measuring 12.3 cm in greatest dimension;
however, it also showed significantly more macroscopic
fat (Fig. 4). Again, splenic and osseous changes related to
SCD were demonstrated.
The patient’s initial laboratory investigations were
unremarkable. Hemoglobin was 13.1 g/dL (reference range
is 13.7 to 17.5 g/dL), white blood cell count was 7.4 103/µL
(reference range is 3.7 to 10.3 103/µL), platelet count was
113 103/µL (reference range is 155 to 369 103/µL), mean
corpuscular volume was 78 fL (reference range is 79 to 98
fL), and mean corpuscular hemoglobin was 28 pg (reference range is 26 to 32 pg).
His biochemical investigations were also normal.
Normetanephrine was 0.35 nmol/L (reference range is <0.9
nmol/L), metanephrine was <0.2 nmol/L (reference range
is <0.5 nmol/L), serum bilirubin was 1.7 mg/dL (reference
range is 0.2 to 1.1 mg/dL), blood urea was 8 mg/dL (reference range is 7 to 21 mg/dL), serum creatinine was 1.0 mg/
dL (reference range is 0.8 to 1.3 mg/dL), total calcium was
8.8 mg/dL (reference range is 8.9 to 10.2 mg/dL), fasting
blood glucose was 401 mg/dL (reference range is 74 to 99
mg/dL), alanine aminotransferase was 64 IU/dL (reference
range is 11 to 41 IU/dL), and aspartate aminotransferase
was 43 IU/dL (reference range is 12 to 40 IU/dL). A lowdose dexamethasone suppression test showed appropriate
suppression with a morning cortisol level of 1.7 µg/dL
(reference range is <1.8 µg/dL).

B

Fig. 2. Graph of tumor size (A) in August 2001, August 2011, January 2015, July 2015, and March 2018 measured on axial computed tomography images. Multiple axial computed tomography images (B) showing growth of the fat-containing right adrenal mass over time (white arrows).
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Fig. 3. (A) Axial T1-weighted magnetic resonance image (MRI) with fat saturation pre-contrast. Axial in-phase (B) and outof-phase (C) T1 MRIs show a right adrenal mass with a decrease in signal intensity on the out-of-phase image and regions of
India ink artifact indicating the presence of intracellular and extracellular lipids. (D) Axial T2-weighted MRI with fat saturation. (E) Axial T2 single-shot fast spin echo MRI shows an 8.4-cm mass with intermediate T2 hyperintense mass involving
the right adrenal gland. Axial diffusion-weighted images with low b-value (F), high b-value (G), and corresponding apparent
diffusion coefficient (H) demonstrating mild restricted diffusion. MRI = magnetic resonance image.

hematology for appropriate SCD management and had an
episode of sickle cell crisis 1 year after the surgery.
DISCUSSION

Fig. 4. Noncontrast axial computed tomography image showing a
large heterogenous adrenal mass containing macroscopic fat. The mass
measured 12.3 × 12.1 × 9.3 cm.

The patient was readmitted to the hospital in 2019
for a sickle cell crisis with a hemoglobin of 8.6 g/dL
(reference range is 13.7 to 17.5 g/dL) and platelet count
of 83 103/µL (reference range is 155 to 369 103/µL). An
uncomplicated laparoscopic hand-assisted right adrenalectomy was performed with an uneventful postoperative
course. The specimen measured 17.0 × 14.5 × 8.0 cm.
Scant adrenal tissue was identified on the surface of the
mass which measured 3.7 × 0.7 cm. The definitive diagnosis was confirmed with histopathology and revealed AM.
The patient has been non-compliant with following up with

The presence of macroscopic fat within an adrenal
mass at imaging is suggestive of AM in most cases (1,2).
However, mass-forming extramedullary hematopoiesis
(EMH) is another type of fat-containing mass that should
be considered in the differential diagnosis in patients
with hematologic disorders. Myelolipoma of the adrenal
gland is a benign tumor that consists of mature fat cells
and hematopoietic cells such as myeloid tissue. AMs are
asymptomatic in most cases but can cause abdominal pain,
flank pain, mass-effect, or retroperitoneal hemorrhage in
large sizes. These tumors are incidentally found in the
course of abdominal cross-sectional imaging evaluation or
at autopsy (1-3).
EMH is a physiological response secondary to insufficient blood cell production and bone marrow function
(4-6). EMH can be seen in hematologic diseases such
as hemoglobinopathies, myeloproliferative disorders,
lymphomas, leukemia, and hemolytic anemias (4,5). EMH
commonly occurs outside of the bone marrow in the reticuloendothelial system such as the spleen and liver, but can
rarely be seen in organs such as brain, adrenals, pleura,
bowel, and breast (7-10). EMH in the adrenals is rare and
is thought to be a compensatory mechanism secondary to
altered hematopoiesis in patients with hemolytic disorders
(8). A few cases of EMH involving the adrenal glands have
been reported in patients with SCD, beta-thalassemia, and
hereditary spherocytosis (5,7-9).
The pathogenesis of AM in SCD is unknown. One of
the proposed theories is that increased erythropoietin levels
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in chronic hemolytic disease might stimulate metaplasia of
embryonic stem cells to myeloid tissue (11). Multiple cases
of AM have been reported in patients with thalassemia
and SCD (12-14). There is no documented association
between hemolytic diseases and AM. However, it is possible that the hematopoietic stress in chronic anemia stimulates the metaplasia of adrenal stromal cells to myeloid
tissue and results in the rapid growth of the tumor in this
population (15).
AMs and mass-forming EMH share common characteristics on imaging and histology. On imaging, AM
is confidently diagnosed when an encapsulated mass
originating from the adrenal gland contains fatty tissue.
Adrenal EMH, often similar in appearance, appears as
a well-defined mass composed of fat and variable internal soft-tissue. On histology, they are both composed of
mature adipose tissue and variable amounts of hematopoietic elements (2,3,16). Genetic evaluation to confirm
clonal origin of myelolipomas has been reported and may
be helpful to distinguish EMH when clinical history is
confounding (16,17). Therefore, EMH maybe underdiagnosed in this patient population, as genetic evaluation is
not routinely performed.
Management of fatty adrenal masses is dependent on
the tumor size, symptoms, and suspicion for malignancy.
There have been multiple studies on treatment guidelines.
Yalagachin and Bhat (18) suggested that surgery is indicated in functional tumors or tumors ≥6 cm. Smaller tumors
with benign imaging characteristics can be managed
conservatively. Bokhari et al (19) concluded that patients
with symptomatic tumors or tumors >7 cm can undergo
elective surgical resection. Laparoscopic is the standard
surgical approach due to minimal postoperative complications, blood loss, and shorter hospital length of stay.
However, open resection might be a better option for lesions
≥10 cm (20).
In this case, the patient was clinically asymptomatic
and his tumor was metabolically inactive. However, due
to the size of the mass and its significant growth over
time, surgical excision was performed and the tumor was
successfully removed by right laparoscopic hand-assisted adrenalectomy. Pathological studies of the specimen
confirmed the diagnosis of AM. Genetic testing of the
specimen was not performed as this was unlikely to alter
the clinical management.
CONCLUSION
Rare cases of rapidly enlarging AM can be seen
in patients with hematologic disorders. AM are benign
neoplasms that can be difficult to differentiate from EMH.
Percutaneous needle biopsy might be indicated if the diag-

nosis remains unclear. Management of AM depends on the
size and symptoms. Surgical excision is recommended in
symptomatic patients or lesions ≥10 cm (18). Smaller or
asymptomatic lesions should be managed conservatively.
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